R-Pralatrexate is a synthetic antifolate compound primarily used in the treatment of certain types of cancer, particularly peripheral T-cell lymphoma. It is a derivative of methotrexate and functions as a dihydrofolate reductase inhibitor, disrupting folate metabolism and thereby inhibiting DNA synthesis in rapidly dividing cells. The compound is characterized by its high affinity for the reduced folate carrier, which facilitates its uptake into cancer cells. R-Pralatrexate is administered intravenously and is known for its ability to penetrate tissues effectively, including the central nervous system. Its pharmacokinetics involve rapid distribution and metabolism, with a relatively short half-life. Common side effects may include myelosuppression, mucositis, and gastrointestinal disturbances, reflecting its impact on both cancerous and healthy rapidly dividing cells. As a targeted therapy, R-Pralatrexate represents a significant advancement in the treatment of malignancies that are resistant to conventional therapies, highlighting the importance of folate metabolism in cancer biology.

R-Pralatrexate

1320211-70-8: R-Pralatrexate is a synthetic antifolate compound primarily used in the treatment of certain types of cancer, particularly peripheral T-cell lymphoma. It is a derivative of methotrexate and functions as a dihydrofolate reductase inhibitor, disrupting folate metabolism and thereby inhibiting DNA synthesis in rapidly dividing cells. The compound is characterized by its high affinity for the reduced folate carrier, which facilitates its uptake into cancer cells. R-Pralatrexate is administered intravenously and is known for its ability to penetrate tissues effectively, including the central nervous system. Its pharmacokinetics involve rapid distribution and metabolism, with a relatively short half-life. Common side effects may include myelosuppression, mucositis, and gastrointestinal disturbances, reflecting its impact on both cancerous and healthy rapidly dividing cells. As a targeted therapy, R-Pralatrexate represents a significant advancement in the treatment of malignancies that are resistant to conventional therapies, highlighting the importance of folate metabolism in cancer biology.

<p>Pralatrexate is a high-affinity DHFR inhibitor targeting RFC-1, used in cancer treatment and immunosuppression.</p>

CAS 1320211-70-8

R-Pralatrexate

R-Pralatrexate

Ref: 4Z-P-197003

R-Pralatrexate

Ref: ST-EA-CP-P117010

Pralatrexate, (R)-

Ref: TM-T25980